Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clobutinol is a small molecule, non-opioid, centrally acting cough suppressant. Initially approved in 1961, it was widely used for the symptomatic relief of persistent, dry, non-productive cough. However, it was withdrawn from the market worldwide in 2007 and 2008 due to significant safety concerns. Studies revealed its potential to cause cardiac arrhythmias by prolonging the QT interval, primarily through the blockade of the hERG potassium channel.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Clobutinol.